Nasonex Nasal Spray / Pump

Mometasone Furoate
50mcg/Dose
Schering-Plough Labo N.V.
Pack size 120 Metered Dose Spray Unit
Dispensing mode POM
Source BELGIUM
AgentCITY MEDICAL STORE
Retail Price 66.50 AED

Indications

Nasonex Nasal Spray / Pump is used for: Allergic rhinitis, Nasal polyps, Asthma prophylaxis

Adult Dose

Nasal Allergic rhinitis Adult: Nasal Treatment and prophylaxis of allergic rhinitis Adults: 100 mcg (2 sprays) in each nostril once daily, increased to 200 mcg into each nostril once daily if needed. Maintenance: 50 mcg in each nostril daily. In patients with a known seasonal allergen that precipitates nasal symptoms of seasonal allergic rhinitis, prophylaxis with Mometasone Nasal Spray is recommended 2 to 4 weeks prior to the anticipated start of the pollen season. Nasal polyps: 100 mcg (2 sprays) in each nostril once daily; may increase to bid after 5-6 wk if needed. Inhalation Asthma prophylaxis: Mild to moderate: Initially, 400 mcg once daily in the evening. Maintenance: 200 mcg once to bid. Severe: Initially, 400 mcg bid, then titrated to lowest effective dose once controlled. Child: Mild to moderate: Initially, 400 mcg once daily. Maintenance: 200 mcg once to bid. Severe: Initially, 400 mcg bid, then titrated to lowest effective dose once controlled.

Child Dose

Nasal Allergic rhinitis Child: 2-11 yr: 50 mcg (1 spray) in each nostril daily; Child: >12 yr: 100 mcg in each nostril daily. Inhalation Asthma prophylaxis: Child: Mild to moderate: Initially, 400 mcg once daily. Maintenance: 200 mcg once to bid. Severe: Initially, 400 mcg bid, then titrated to lowest effective dose once controlled.

Renal Dose

Administration

Contra Indications

Hypersensitivity, Immunosuppressed patients, Tuberculosis, Status asthmaticus or other acute asthma episode necessitating intensive measures, Known hypersensitivity to milk proteins or any other ingredients

Precautions

Respiratory tract tuberculosis, untreated fungal or bacterial infections, viral or parasitic infections, ocular herpes simplex Nasal septum perforation, epistaxis, wheezing Cataracts, glaucoma, increased intraocular pressure Risk of more serious or fatal course of chickenpox and measles in susceptible individuals; avoid use in unvaccinated or immunologically unexposed children or adults Deaths from adrenal insufficiency have occurred after abrupt withdrawal of oral steroids; taper withdrawal gradually May retard growth in children Immunocompromised patients Infections of nose and pharynx, including Candida albicans Excessive use may suppress hypothalamic-pituitary-adrenal function During periods of stress or severe status asthmaticus, patient may require supplementary systemic corticosteroids immediately; carry warning card to that effect Long-term administration reduces bone mineral density

Pregnancy-Lactation

Pregnancy Inhalation There are no randomized clinical studies in pregnant women Clinical considerations In women with poorly or moderately controlled asthma, there is an increased risk of several perinatal adverse outcomes such as preeclampsia in the mother and prematurity, low birth weight, and small for gestational age in the neonate Closely monitor pregnant women with asthma and adjust medication as necessary to maintain optimal asthma control Lactation There are no available data on the presence in human milk, the effects on the breastfed child, or the effects on milk production Other inhaled corticosteroids, similar to mometasone furoate, are present in human milk Consider developmental and health benefits of breastfeeding along with the mother’s clinical need and any potential adverse effects on the breastfed infant from mometasone inhaled or from the underlying maternal condition Nasal Pregnancy category: C Lactation: Unknown whether distributed in breast milk

Interactions

Increased risk of hypokalaemia with amphotericin B, potassium-wasting diuretics. Decreases hypoglycaemic effects of antidiabetic drugs. Increased serum levels with antifungals (imidazole). Increased risk of tendinopathies with fluoroquinolones.

Adverse Effects

Side effects of Mometasone Furoate : >10% Headache (26%), Viral infection (14%), Pharyngitis (12%), Epistaxis (11%) 1-10% Cough (7%), Upper respiratory tract infection (6%), Dysmenorrhea (5%) Frequency Not Defined Loss of taste, Muscle soreness

Mechanism of Action

Mometasone depresses the formation, release and activity of endogenous inflammatory chemical mediators (e.g. kinins, histamine, liposomal enzymes and prostaglandin). It inhibits the margination and subsequent cell migration to the injury site, reverses vascular dilatation and permeability, resulting in decreased access of cells to the area of injury.

Note

Nasonex 50mcg/Dose Nasal Spray / Pump manufactured by Schering-Plough Labo N.V.. Its generic name is Mometasone Furoate. Nasonex is availble in United Arab Emirates. Farmaco UAE drug index information on Nasonex Nasal Spray / Pump is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.

Some other brands of Mometasone Furoate :